*Ophthalmology Department, Dijon-Bourgogne University Hospital, Dijon, France;
†Clinical Epidemiology Unit, Inserm, CIC 1432, Dijon, France;
‡Clinical Epidemiology/Clinical Trials Unit, Dijon-Bourgogne University Hospital, Clinical Investigation Center, Dijon, France;
§Eye and Nutrition Group, Centre des Sciences du Goût et de l'Alimentation, CNRS, INRAe, University Bourgogne Franche-Comté, Dijon, France;
¶Bordeaux Population Health Research Center, University of Bordeaux, Inserm, Team LEHA, UMR 1219, Bordeaux, France;
**Department of Ophthalmology, Gui de Chauliac Hospital, Montpellier, France; and
††Inserm, U1061, Montpellier, France.
Reprint requests: Catherine Creuzot-Garcher, MD, PhD, Service d'Ophtalmologie, CHU Dijon, 14 Rue Gaffarel, 21000 Dijon, France; e-mail: [email protected]
Supported by an interregional grant (PHRC) and the Regional Council of Burgundy.
C. Delcourt reported consulting for Allergan, Bausch & Lomb, Théa, Novartis, and Roche. A. M. Bron reported consulting for Aerie, Allergan SAS, Bausch & Lomb, Santen, and Théa. C. Creuzot-Garcher reported consulting for Allergan SAS, Bausch & Lomb, Bayer HealthCare, Horus Pharma, Novartis Pharma SAS, Roche, and Théa. The remaining authors has any conflicting interests to disclose.